Plant-produced monoclonal antibody enters Phase I
Clinical trials of a monoclonal antibody produced in transgenic tobacco plants, a potentially low-cost, scalable system, have begun in Europe.
Clinical trials of a monoclonal antibody produced in transgenic tobacco plants, a potentially low-cost, scalable system, have begun in Europe.
Filtration, separation and purification technology company Pall is to acquire its long-time Brazilian distribution partner, Engefiltro.